Fujitsu Technology Solutions Selects AppliedMicro’s QT2225 PHY ICs for High-Speed 10GBASE-KR Backplane Server Interconnect
Highly Reliable 10Gbps Ethernet Connectivity Paves Way for High-Volume, Low Cost Adoption and Provides High-Performance Infrastructure for Virtualization and Cloud Computing Applications
Fujitsu Technology Solutions Selects AppliedMicro’s QT2225 PHY ICs for High-Speed 10GBASE-KR Backplane Server Interconnect
AppliedMicro (NASDAQ:AMCC), a global leader in silicon solutions to process, transport and store applications, today announced that Fujitsu Technology Solutions, a leading European IT infrastructure provider, has selected AppliedMicro’s QT2225 10GBASE-KR physical layer device (PHY) for 10-Gigabit per second Ethernet connectivity over copper traces for its PRIMERGY BX900 Blade System.
“Ethernet backplane serial connectivity at 10 Gbps data rate is highly desirable for server virtualization and consolidation applications but it must come with robust performance and low cost,” said Bernhard Brandwitte, director of Product Marketing for x86 Servers at Fujitsu Technology Solutions. “AppliedMicro’s QT2225 device brings that high-speed connectivity to server backplanes through 10GBASE-KR application. The PHY excels in harsh blade system environments and enables a low per-port system cost through a high level of integration and reduced system complexity.”
The QT2225 is a low power dual port XAUI-to-10GBASE-KR PHY IC designed for transmission of serial 10 Gbps Ethernet traffic over one meter of PCB/backplane. It includes integrated IEEE Std. 802.3apTM -2007 FEC with bypass and can operate in both 10GBASE-KR and 1000BASE-KX mode. Interoperability has been demonstrated with other 10GBASE-KR vendors and in multiple blade system configurations.
“As one of the world’s leading server vendors, Fujitsu Technology Solutions was concerned about the key design areas that create bottlenecks in I/O performance. AppliedMicro’s design team worked closely with Fujitsu to ensure that the QT2225 met the lossy, high noise conditions of a blade system backplane,” said Sandeep Gupta, GM of Transport Products at AppliedMicro. “Through this type of close cooperation, AppliedMicro has developed a PHY technology that can tackle the demanding conditions of today’s data centers, placing the company in an ideal position as 10GBASE-KR technology starts to hit high-volume production.”
AppliedMicro Overview
AppliedMicro is a global leader in energy efficient sustainable solutions to process, transport, and store information for the next generation of Internet data center and carrier central office. A leader in high speed signal processing, IP and Ethernet packet processing, and processors, AppliedMicro's patented innovations provide high value solutions in telecom, enterprise and consumer applications. AppliedMicro's corporate headquarters are located in Sunnyvale, California. Sales and engineering offices are located throughout the world. For further information regarding AppliedMicro, visit the company’s Web site at http://www.appliedmicro.com .
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as expects, anticipates, plans, believes, estimates, will or words of similar meaning. Such forward-looking statements, including statements relating to the products discussed in this press release, are subject to a number of risks and uncertainties, including the risk that the products may not be successfully or timely developed, completed or manufactured or achieve market acceptance, risks relating to general economic conditions, as well as the risks and uncertainties set forth in the Company's Annual Report on Form 10-K, and in the Company's other SEC filings. As a result of these risks and uncertainties, actual results may differ materially from these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and AppliedMicro does not assume any obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Contact:
AppliedMicro
Kathy Ligon, 408-702-3127 (Corporate)
Cell:
408-455-3985
kligon@AppliedMicro.com
or
The
Bernard Group
Tom Murphy, 408-370-6601 (Media)
Cell:
831-402-4142
tmurphy@bernardgroup.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom